MedTrace Logo

Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients

NCT06326619 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2024-03-22

No results posted yet for this study

Summary

About 20-25 percent of all colorectal cancer patients are diagnosed with International Union Against Cancer (UICC) stage IV disease. The benefit of primary tumor resection in the palliative context is therefore of high concern. However, empirical evidence from randomized and observational studies is inconsistent.

The objective of the present study is to compare the survival of palliative stage IV colorectal cancer patients selected for primary tumor resection and systemic treatment (PTR+SYST) to patients with systemic treatment only (SYST).

Conditions

Interventions

PROCEDURE

Primary tumor resection

In addition to systemic therapy a primary tumor resection was performed.

PROCEDURE

Systemic Therapy

chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis

Sponsors & Collaborators

  • Clinical-Epidemiological Cancer Registry Brandenburg-Berlin

    collaborator UNKNOWN

  • Medizinische Hochschule Brandenburg Theodor Fontane

    lead OTHER

Principal Investigators

  • Rene Mantke, M.D. · Medizinische Hochschule Brandenburg CAMPUS GmbH

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2020-12-31
Completion
2020-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06326619 on ClinicalTrials.gov